Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.72 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.72 |
| ▸ | ALOX15B | O15296 | 3/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | TTR | P02766 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30912709 | 1.00 | ALOX15 (0.72) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL30933011 | 1.00 | ALOX15 (0.72) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL571151 | 0.84 | ALOX12 (1.00) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL17963715 | 0.82 | ESR1 (0.67) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL30932995 | 0.82 | ESR1 (0.67) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL30851574 | 0.82 | ESR1 (0.67) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| Glycitein SCHEMBL4653829 | 0.82 | HDAC6 (0.67) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL8118137 | 0.82 | ALOX15 (0.72) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL28900364 | 0.81 | ALOX15 (0.54) | ALOX15ALOX12ALOX15BESR1ESR2 | |
| SCHEMBL10562731 | 0.81 | ALOX15 (1.00) | ALOX15ALOX12ALOX15BESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312408-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN | 2009-12-17 | — | — | US | claimed |
| EP-1991538-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | Adlercreutz, Herman (FI) | 2008-11-19 | — | — | EP | claimed |
| WO-2007096471-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN (FI) | 2007-08-30 | — | — | WO | claimed |
| US-20070203227-A1 | Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors | ADLERCREUTZ HERMAN | 2007-08-30 | — | — | US | claimed |
| US-20250051551-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2025-02-13 | — | — | US | disclosed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240355451-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | NESTLE SA (CH) | 2024-10-24 | — | — | US | disclosed |
| EP-4391834-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20240101791-A1 | POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024059282-A1 | IMPROVED POLYMER COMPOSITES | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-03-21 | — | — | WO | disclosed |
| US-20230255989-A1 | GLYCAN COMPOSITIONS AND USES THEREOF | DSM NUTRITIONAL PRODUCTS LLC (US) | 2023-08-17 | — | — | US | disclosed |
| WO-2023025722-A1 | METHODS FOR IMPROVING GUT MICROBIOTA DIVERSITY | Société des Produits Nestlé S.A. (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-9492473-B2 | Glycan therapeutics and related methods thereof | KALEIDO BIOSCIENCES, INC. (US) | 2016-11-15 | — | — | US | disclosed |
| EP-3071235-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | Kaleido Biosciences, Inc. (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2016122889-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-20160213702-A1 | GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF | KALEIDO BIOSCIENCES, INC. (US) | 2016-07-28 | — | — | US | disclosed |
| US-20090312408-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN | 2009-12-17 | — | — | US | disclosed |
| EP-1991538-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | Adlercreutz, Herman (FI) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007096471-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | ADLERCREUTZ HERMAN (FI) | 2007-08-30 | — | — | WO | disclosed |
| US-20070203227-A1 | Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors | ADLERCREUTZ HERMAN | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203227-A1 | Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors | VEGFA, FLT1, FLT4 | ALOX15 1341/4885ALOX12 1178/4885ALOX15B 1494/4885 |
| US-20090312408-A1 | ISOFLAVAN AND ISOFLAVENE COMPOUNDS AND THEIR USE AS ANGIOGENESIS INHIBITORS | VEGFA, PGF, HIF1AN | ALOX15 1855/4885ALOX12 1763/4885ALOX15B 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.